Medium chain triglyceride compositions
A composition comprising medium-chain triglycerides (MCTs) wherein the composition comprises (i) a MCT comprising three fatty acid moieties each with 8 carbon atoms (MCT-C8) and (ii) a MCT comprising three fatty acid moieties each with 10 carbon atoms (MCT-C10); wherein the ratio of MCT-C8 to MCT-C10 is from 10:90 to 90:10 (mol/mol) and wherein the combined amount of MCT-C8 and MCT-C10 make up at least 50 mol % of the MCTs in the composition.
1. A method of treating an individual having a brain energy deficiency condition or disease, the method comprising administering a composition comprising medium-chain triglycerides (MCTs) to the individual, wherein the MCTs comprise:
a MCT comprising three fatty acid moieties each with 8 carbon atoms (MCT-C8); and
a MCT comprising three fatty acid moieties each with 10 carbon atoms (MCT-C10);
wherein the ratio of the MCT-C8 to the MCT-C10 is from 10:90 to 90:10 (mol/mol), wherein at least 95 mol % of the MCTs in the composition are MCT-C8 and MCT-C10, and
wherein the composition provides increased ketones and/or fatty acids as compared to a composition comprising MCTs comprising three fatty acids moieties each with a mix of C8 and C10 moieties attached and having the same C8/C10 ratio and molar amounts.
2. The method according to claim 1 wherein the ratio of MCT-C8 to MCT-C10 is 20:80 to 85:15 (mol/mol).
3. The method according to claim 1 wherein at least 98 mol % of the MCTs in the composition are MCT-C8 and MCT-C10.
4. A method of treating an individual having a condition or disease that is neurological and/or associated with brain energy deficiency, the method comprising administering a composition comprising medium-chain triglycerides (MCTs) to the individual, wherein the MCTs comprise:
a MCT comprising three fatty acid moieties each with 8 carbon atoms (MCT-C8); and
a MCT comprising three fatty acid moieties each with 10 carbon atoms (MCT-C10);
wherein the ratio of the MCT-C8 to the MCT-C10 is from 50:50 to 67:33 (mol/mol), and
wherein the composition provides increased ketones and/or fatty acids as compared to a composition comprising MCTs comprising three fatty acids moieties each with a mix of C8 and C10 moieties attached and having the same C8/C10 ratio and molar amounts.
5. The method according to claim 1 , wherein the three fatty acid moieties each with 8 carbon atoms are octanoic acid moieties, and/or the three fatty acid moieties each with 10 carbon atoms are decanoic acid moieties.
6. The method according to claim 1 , wherein the composition further comprises one or more agents that promote or sustain neurologic health or enhance cognitive function, wherein the one or more agents are selected from the group consisting of vitamins, choline, phosphatidylserine, alpha-lipoic acid, CoQ10, acetyl-L-carnitine, herbal extracts, omega-3 or omega-6 polyunsaturated fatty acids, aliphatic ester, fish oil extracts, and mixtures thereof.
7. The method according to claim 4 , wherein the three fatty acid moieties each with 8 carbon atoms are octanoic acid moieties, and/or the three fatty acid moieties each with 10 carbon atoms are decanoic acid moieties.
8. The method according to claim 4 , wherein the composition further comprises one or more agents that promote or sustain neurologic health or enhance cognitive function, wherein the one or more agents are selected from the group consisting of vitamins, choline, phosphatidylserine, alpha-lipoic acid, CoQ10, acetyl-L-carnitine, herbal extracts, omega-3 or omega-6 polyunsaturated fatty acids, aliphatic ester, fish oil extracts, and mixtures thereof.
9. The method according to claim 1 , wherein the ratio of the MCT-C8 to the MCT-C10 is 58:42 to 62:38 (mol/mol).
10. The method according to claim 1 , wherein the composition provides increased ketones and/or fatty acids as compared to a composition comprising MCTs comprising three fatty acids moieties each with a mix of C8 and C10 moieties attached and having the same C8/C10 ratio and molar amounts.
11. The method according to claim 1 , wherein the condition or disease is selected from the group consisting of migraine, memory disorder, age-related memory disorder, brain injury, stroke, amyloid lateral sclerosis, multiple sclerosis, cognitive impairment, cognitive impairment post-intensive care, age-induced cognition impairment, Alzheimer's disease, Parkinson's disease, Huntingdon's disease, an inherited metabolic disorder, bipolar disorder, schizophrenia, epilepsy and combinations thereof.
12. The method according to claim 4 , wherein the condition or disease is selected from the group consisting of migraine, memory disorder, age-related memory disorder, brain injury, stroke, amyloid lateral sclerosis, multiple sclerosis, cognitive impairment, cognitive impairment post-intensive care, age-induced cognition impairment, Alzheimer's disease, Parkinson's disease, Huntingdon's disease, an inherited metabolic disorder, bipolar disorder, schizophrenia, epilepsy and combinations thereof.
13. The method according to claim 11 , wherein the inherited metabolic disorder is selected from the group consisting of glucose transporter type 1 deficiency syndrome and pyruvate dehydrogenase complex deficiency.
14. The method according to claim 12 , wherein the inherited metabolic disorder is selected from the group consisting of glucose transporter type 1 deficiency syndrome and pyruvate dehydrogenase complex deficiency.